Frontiers in Pharmacology (Aug 2020)

Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study

  • Anushi E. Rajapaksa,
  • Anushi E. Rajapaksa,
  • Anushi E. Rajapaksa,
  • Lien Anh Ha Do,
  • Lien Anh Ha Do,
  • Darren Suryawijaya Ong,
  • Darren Suryawijaya Ong,
  • Magdy Sourial,
  • Duncan Veysey,
  • Richard Beare,
  • Richard Beare,
  • William Hughes,
  • William Yang,
  • Robert J. Bischof,
  • Robert J. Bischof,
  • Amarin McDonnell,
  • Peter Eu,
  • Leslie Y. Yeo,
  • Paul V. Licciardi,
  • Paul V. Licciardi,
  • Edward K. Mulholland,
  • Edward K. Mulholland,
  • Edward K. Mulholland

DOI
https://doi.org/10.3389/fphar.2020.01291
Journal volume & issue
Vol. 11

Abstract

Read online

ObjectiveCurrent prevention and/or treatment options for respiratory syncytial virus (RSV) infections are limited as no vaccine is available. Prophylaxis with palivizumab is very expensive and requires multiple intramuscular injections over the RSV season. Here we present proof-of-concept data using nebulized palivizumab delivery as a promising new approach for the prevention or treatment of severe RSV infections, documenting both aerosol characteristics and pulmonary deposition patterns in the lungs of lambs.DesignProspective animal study.SettingBiosecurity Control Level 2-designated large animal research facility at the Murdoch Children’s Research Institute, Melbourne, Australia.SubjectsFour weaned Border-Leicester/Suffolk lambs at 5 months of age.InterventionsFour lambs were administered aerosolized palivizumab conjugated to Tc-99m, under gaseous anesthesia, using either the commercially available AeroNeb Go® or the investigational HYDRA device, placed in-line with the inspiratory limb of a breathing circuit. Lambs were scanned in a single-photon emission computed tomography (SPECT/CT) scanner in the supine position during the administration procedure.Measurements and Main ResultsBoth the HYDRA and AeroNeb Go® produced palivizumab aerosols in the 1–5 µm range with similar median (geometric standard deviation and range) aerosol droplet diameters for the HYDRA device (1.84 ± 1.40 μm, range = 0.54–5.41μm) and the AeroNeb Go® (3.07 ± 1.56 μm, range = 0.86–10 μm). Aerosolized palivizumab was delivered to the lungs at 88.79–94.13% of the total aerosolized amount for all lambs, with a small proportion localized to either the trachea or stomach. No difference between devices were found. Pulmonary deposition ranged from 6.57 to 9.25% of the total dose of palivizumab loaded in the devices, mostly in the central right lung.ConclusionsAerosolized palivizumab deposition patterns were similar in all lambs, suggesting a promising approach in the control of severe RSV lung infections.

Keywords